We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
+5.42%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$6.42M
Cap. Flow
-$4.09M
Cap. Flow %
-2.97%
Top 10 Hldgs %
92.68%
Holding
18
New
–
Increased
–
Reduced
2
Closed
1
Avg Time Held
1.7 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
1.7 years

Top Buys

No buys this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CRSP icon
1
CRISPR Therapeutics
CRSP
$3.97B
$45.8M 33.18%
1,951,359
-20,548
-1% -$390K
2016 Q4
4 quarters
SIEN
2
DELISTED
Sientra
SIEN
$30.9M 22.35%
219,901
– –
2014 Q4
12 quarters
PRTK
3
DELISTED
Paratek Pharmaceuticals
PRTK
$18.6M 13.5%
1,041,131
– –
2014 Q4
12 quarters
CBAY icon
4
DELISTED
Cymabay Therapeutics
CBAY
$10.6M 7.65%
1,147,077
-395,645
-26% -$3.38M
2015 Q3
9 quarters
OBSV
5
DELISTED
ObsEva
OBSV
$4.29M 3.11%
440,000
– –
2017 Q3
1 quarter
ONCT icon
6
DELISTED
Oncternal Therapeutics
ONCT
$4.28M 3.1%
2,423
– –
2017 Q3
1 quarter
TARA icon
7
Protara Therapeutics
TARA
$142M
$3.73M 2.7%
50,447
– –
2014 Q4
12 quarters
CHMA
8
DELISTED
Chiasma
CHMA
$3.43M 2.49%
2,080,595
– –
2015 Q3
9 quarters
CASC
9
DELISTED
Cascadian Therapeutics
CASC
$3.42M 2.48%
925,000
– –
2017 Q1
3 quarters
CLLS icon
10
Cellectis
CLLS
$108M
$2.92M 2.11%
100,000
– –
2015 Q4
8 quarters
DERM icon
11
DELISTED
Dermira
DERM
$1.95M 1.41%
70,000
– –
2015 Q3
9 quarters
OCGN icon
12
Ocugen
OCGN
$248M
$1.8M 1.31%
14,815
– –
2016 Q3
5 quarters
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$1.78B
$1.77M 1.28%
38,100
– –
2017 Q3
1 quarter
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$1.67M 1.21%
250,000
– –
2015 Q4
8 quarters
IMDZ
15
DELISTED
Immune Design
IMDZ
$1.37M 1%
352,300
– –
2016 Q2
6 quarters
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$2.03B
$1.14M 0.83%
252,129
– –
2017 Q1
3 quarters
EVAR
17
DELISTED
Lombard Medical
EVAR
$399K 0.29%
3,473,452
– –
2014 Q3
13 quarters
INNL
18
DELISTED
Innocoll Holdings
INNL
– –
-537,235
Closed -$322K –

Similar funds

Abingworth's Q4 2017 Portfolio in Review

As of Q4 2017, Abingworth held 18 positions worth $138M, down 4.4% from $144M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Abingworth's Q4 2017 filing shows 2 reduced and 1 closed positions. The largest sale was Cymabay Therapeutics, an estimated $3.38M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Abingworth's biggest Q4 2017 reduction was Cymabay Therapeutics, cutting an estimated $3.38M.
  • Abingworth fully exited Innocoll Holdings in Q4 2017, selling an estimated $322K.
  • Abingworth's ten largest holdings make up 93% of its $138M portfolio in Q4 2017.
  • Abingworth opened 0 new positions and closed 1 in Q4 2017.
  • Abingworth's portfolio value fell 4.4% quarter-over-quarter to $138M.

Based on Abingworth's 13F filing for Q4 2017, filed 14 Feb 2018.